Biosimilars

The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.

Latest News

Wooden blocks spelling biosimilars -- Image credit: lexiconimages | stock.adobe.com
Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

June 12th 2025

Biologics and biosimilars have a major role in modern medicine because of their clinical benefits and economic impact on patient care.

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems
Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

June 10th 2025

Op-Ed: Expand Patient Choice to Lower Medication Costs
Op-Ed: Expand Patient Choice to Lower Medication Costs

June 6th 2025

An anonymous man injecting a treatment such as insulin or adalimumab, etanercept or epinephrine into his shoulder. It is a white pen injector with red head for health care. - Image credit: LaMorenita | stock.adobe.com
FDA Grants Interchangeability Designation to Hadlima, a Biosimilar for Humira

June 2nd 2025

Prague, Czech Republic - August 28 2024: STELARA box with USTEKINUMAB active substance by JANSSEN, used for psoriasis, Crohn’s disease, and ulcerative colitis.
FDA Approves Ustekinumab-hmny Injection, a Biosimilar Referencing Stelara

May 28th 2025

<1
...
1617181920